Updating molecular properties during early drug discovery

Drug Discovery Today

Volumn 22, Issue 6, 2017, Pages 835-840

  Caron, Giulia ^a   Ermondi, Giuseppe ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OCTANOL; DRUG;

BASE DISSOCIATION CONSTANT; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; HYDROGEN BOND; LIPOPHILICITY; MOLECULAR BIOLOGY; ORAL ABSORPTION; PHYSICAL CHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SHORT SURVEY; CHEMICAL PHENOMENA; CHEMISTRY;

CHEMICAL PHENOMENA; DRUG DISCOVERY; PHARMACEUTICAL PREPARATIONS;

EID: 85007425423     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.11.017     Document Type: Short Survey

References (29)

1. Gleeson, M.P., et al. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10 (2011), 197–208.
2. Leeson, P.D., Young, R., Molecular property design: does everyone get it?. ACS Med. Chem. Lett. 6 (2015), 722–725.
3. Segall, M.D., et al. Avoiding missed opportunities by analysing the sensitivity of our decisions. J. Med. Chem. 59 (2016), 4267–4277.
4. Giordanetto, F., Kihlberg, J., Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?. J. Med. Chem. 57 (2014), 278–295.
5. Carrupt, P.A., et al. Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J. Med. Chem. 34 (1991), 1272–1275.
6. Manallack, D.T., et al. The significance of acid/base properties in drug discovery. Chem. Soc. Rev. 42 (2013), 485–496.
7. Charifson, P.S., Walters, W.P., Acidic and basic drugs in medicinal chemistry: a perspective. J. Med. Chem. 57 (2014), 9701–9717.
8. Ten Brink, T., Exner, T.E., pKa based protonation states and microspecies for protein–ligand docking. J. Comput. Aid. Mol. Des. 24 (2010), 935–942.
9. Pagliara, A., et al. Lipophilicity profiles of ampholytes. Chem. Rev. 97 (1997), 3385–3400.
10. Pyta, K., et al. Intramolecular proton transfer impact on antibacterial properties of ansamycin antibiotic rifampicin and its new amino analogues. Org. Biomol. Chem., 2012, 2385–2388.
11. Pyta, K., et al. A new model of binding f rifampicin and its amino analogues as zwitterions to bacterial RNA polymerase. Org. Biomol. Chem. 10 (2012), 8283–8297.
12. Williams, H.D., et al. Strategies to address low drug solubility in discovery and development. Pharmacol. Rev. 65 (2013), 315–499.
13. Box, K., et al. New ideas about the solubility of drugs. Chem. Biodiver. 6 (2009), 1767–1788.
14. Avdeef, A., Physicochemical profiling (solubility, permeability and charge state). Curr. Top. Med. Chem. 1 (2001), 277–351.
15. Shore, P.A., et al. The gastric secretion of drugs: a pH partition hypothesis. J. Pharmacol. Exp. Ther. 119 (1957), 361–369.
16. Thomae, A., et al. Permeation of aromatic carboxylic acids across lipid bilayers: the pH–partition hypothesis revisited. Biophys. J. 89 (2005), 1802–1811.
17. Wang, J., Skolnik, S., Permeability diagnosis model in drug discovery: a diagnostic tool to identify the most influencing properties for gastrointestinal permeability. Curr. Top. Med. Chem. 13 (2013), 1308–1316.
18. Settimo, L., et al. Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. Pharm. Res. 31 (2014), 1082–1095.
19. Morgenthaler, M., et al. Predicting and tuning physicochemical properties in lead optimization: amine basicities. ChemMedChem 2 (2007), 1100–1115.
20. Milletti, F., et al. Extending pKa prediction accuracy: high-throughput pK a measurements to understand pKa modulation of new chemical series. Eur. J. Med. Chem. 45 (2010), 4270–4279.
21. Manallack, D.T., The pK(a) distribution of drugs: application to drug discovery. Perspect. Med. Chem. 1 (2007), 25–38.
22. Shalaeva, M., et al. Integrating intramolecular hydrogen bonding (IMHB) considerations in Drug discovery using (Δ log P as a tool. J. Med. Chem. 56 (2013), 4870–4879.
23. Whitty, A., et al. Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs. Drug Discov. Today 21 (2016), 712–717.
24. Labby, K., et al. Intramolecular hydrogen bonding: a potential strategy for more bioavailable inhibitors of neuronal nitric oxide synthase. Bioorg. Med. Chem. 20 (2012), 2435–2443.
25. Alex, A., et al. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. MedChemComm 2 (2011), 669–674.
26. Shalaeva, M., et al. Measurement of dissociation constants (pKa Values) of organic compounds by multiplexed capillary electrophoresis using aqueous and cosolvent buffers. J. Pharm. Sci., 97, 2008, 2581.
27. Caron, G., et al. A fast chromatographic method for estimating lipophilicity and ionization in nonpolar membrane-like environment. Mol. Pharm. 13 (2016), 1100–1110.
28. oct–tol. Eur. J. Pharm. Sci. 53 (2014), 50–54.
29. Cook, D., et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13 (2014), 419–431.